CUE — Cue Biopharma Share Price
0.000.00%
Last trade - 00:00- $57.42m
- $39.29m
- $9.29m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.28 | ||
| Price to Tang. Book | 3.28 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -224.3% | ||
| Return on Equity | -149.03% | ||
| Operating Margin | -446.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.15 | 14.94 | 1.25 | 5.49 | 9.29 | 4.88 | 6.18 | 21.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Directors
- Frank Morich CHM (67)
- Anish Suri PRE (47)
- Daniel Passeri CEO (60)
- Kerri-Ann Millar CFO (51)
- Colin Sandercock SVP (64)
- Patricia Nasshorn OTH
- Kenneth Pienta OTH (61)
- Tamar Howson DRC (72)
- Frederick Driscoll IND (71)
- Aaron Fletcher IND (41)
- Cameron Gray IND (50)
- Peter Kiener IND (69)
- Barry Simon IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 31st, 2014
- Public Since
- January 2nd, 2018
- No. of Shareholders
- 85
- No. of Employees
- 41
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 75,349,881
- Address
- 40 Guest Street, BOSTON, 02135
- Web
- https://www.cuebiopharma.com/
- Phone
- +1 6179492680
- Contact
- Kerri-Ann Millar
- Auditors
- RSM US LLP
Upcoming Events for CUE
Cue Biopharma Inc Annual Shareholders Meeting
Cue Biopharma Inc Annual Shareholders Meeting
Q2 2025 Cue Biopharma Inc Earnings Release
Similar to CUE
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Cue Biopharma share price?
As of Today at 20:08 UTC, shares in Cue Biopharma are trading at $0.76. This share price information is delayed by 15 minutes.
How has the Cue Biopharma share price performed this year?
Shares in Cue Biopharma last closed at $0.76 and the price had moved by -53.25% over the past 365 days. In terms of relative price strength the Cue Biopharma share price has underperformed the S&P500 Index by -56.04% over the past year.
What are the analyst and broker recommendations for Cue Biopharma?
The overall consensus recommendation for Cue Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cue Biopharma dividend yield?
Cue Biopharma does not currently pay a dividend.
Does Cue Biopharma pay a dividend?
Cue Biopharma does not currently pay a dividend.
When does Cue Biopharma next pay dividends?
Cue Biopharma does not currently pay a dividend.
How do I buy Cue Biopharma shares?
To buy shares in Cue Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cue Biopharma?
As of the previous close price of $0.76, shares in Cue Biopharma had a market capitalisation of $57.42m.
Where are Cue Biopharma shares listed?
Here are the trading details for Cue Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CUE
What kind of share is Cue Biopharma?
Based on an overall assessment of its quality, value and momentum Cue Biopharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cue Biopharma share price forecast for 2025?
The analyst consensus target price for shares in Cue Biopharma is $3.50. That is 359.32% above the last closing price of $0.76.
Analysts covering Cue Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.60 for the next financial year.
Find out moreWhat is the trend in the Cue Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cue Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -30.21%.
As of the last closing price of $0.76, shares in Cue Biopharma were trading -27.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cue Biopharma PE Ratio?
The Cue Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cue Biopharma?
Cue Biopharma's management team is headed by:
- Frank Morich - CHM
- Anish Suri - PRE
- Daniel Passeri - CEO
- Kerri-Ann Millar - CFO
- Colin Sandercock - SVP
- Patricia Nasshorn - OTH
- Kenneth Pienta - OTH
- Tamar Howson - DRC
- Frederick Driscoll - IND
- Aaron Fletcher - IND
- Cameron Gray - IND
- Peter Kiener - IND
- Barry Simon - IND